Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of efavirenz in Niemann-Pick disease type C with cognitive impairment
2023-505832-36-01Phase 2Completed
- Sponsor
- Bellvitge University Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in Niemann-Pick disease type C (NPC), sponsored by Bellvitge University Hospital. Primary endpoints: Number of adverse events, Changes in liver function panel and 1 more. Started May 2024; status: completed.
02
Drugs
efavirenz
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on 2023-505832-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505832-36-01.